HR Execs on the Move


 
Founded in 2017 by Carolyn Witte and Felicity Yost, Tia is bringing the new standard of care for women for women in NY, LA, SF and PHX. Blending in-person and virtual care services, Tia`s “Whole Woman, Whole Life” care model fuses gynecology, primary care, mental health and evidence-based wellness services to treat women comprehensively. By bringing collaborative, comprehensive, and compassionate care, Tia is raising the bar for women and empowering them to achieve optimal health, on their terms.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.asktia.com
  • 548 Market Street Suite 45295
    San Francisco, CA USA 94104
  • Phone: 855.586.1306

Executives

Name Title Contact Details
Mary White
Senior Director Growth Marketing Profile
Daria Burke
Global Chief Marketing Officer Profile

Similar Companies

Complete Medical Communications

Complete Medical Communications is a Horsham, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PROJECTFOREVER

YOUR BEST BODY. YOUR BEST LIFE. PROJECTFOREVER IS DEDICATED TO HELPING PEOPLE DO WHAT THEY LOVE AT THEIR HIGHEST POTENTIAL, FREE OF PAIN, FOR AS LONG AS THEY LIVE. With thousands of “impossible” transformations and counting, our proven approach to fitn...

Framingham Heart Study

Since our beginning in 1948, the Framingham Heart Study, under the direction of the National Heart, Lung and Blood Institute (NHLBI), formerly known as the National Heart Institute, has been committed to identifying the common factors or characteristics that contribute to cardiovascular disease (CVD). We have followed CVD development over a long period of time in three generations of participants.

Midwest Medical Svc

Midwest Medical Svc is a Charleston, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OncoCell MDx

OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.